Neel Shah: I think the ARRIVE trial was a very well conducted and necessary study that has been widely misunderstood. Before ARRIVE, it was widely believed that the decision to induce a woman after 39 weeks increases her risk of cesarean. The trial convincingly demonstrates is that this risk is not due to the DECISION to induce but rather HOW the induction is performed. This is a critically important distinction. If the goal is to reduce cesareans we should focus on how labor is managed, regardless of whether a woman is in spontaneous labor or undergoing induction. It does leave several other important questions unanswered: which inductions are truly necessary? How do we ensure clinicians and families are making informed, shared decisions? But these questions are outside the scope of the study itself.